The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer
1 other identifier
observational
100
1 country
1
Brief Summary
The study is going to recruit patients with gastrointestinal cancer, collect clinical data and peripheral blood sample and possible fat samples. The expression of SIRT-6 in peripheral blood will be tested and connect with different status of cachexia of the patients. A mathematical model of the relationship between cachexia classification and SIRT-6 expression is going to constructed as anticipated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 14, 2020
CompletedFirst Posted
Study publicly available on registry
October 20, 2020
CompletedStudy Start
First participant enrolled
November 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2021
CompletedOctober 20, 2020
October 1, 2020
6 months
October 14, 2020
October 14, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
SIRT-6 expression
SIRT-6 expression tested by ELISA
4 months
Study Arms (2)
cachexia
patients suffering from cachexia recently
no cachexia
patients are not suffering from cachexia recently
Eligibility Criteria
Patients who are diagnosed with gastrointestinal cancer for the first time without any chemotherapy or radiotherapy
You may qualify if:
- Age between 18 and 90 years old, unlimited gender;
- Patients who are diagnosed with gastrointestinal cancer for the first time and are planning to undergo further treatment;
- Volunteer to participate and sign the informed consent form.
You may not qualify if:
- Women who are pregnant or lactate;
- Patients with severe metabolic diseases; combined with cardiac function, liver and kidney dysfunction, acute myocardial infarction and acute stroke in the past 3 months , COPD acute onset respiratory failure and other serious medical diseases and patients who need hormone therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking Union Medical College Hospita
Beijing, Beijing Municipality, 100730, China
Related Publications (2)
Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014 Nov;14(11):754-62. doi: 10.1038/nrc3829. Epub 2014 Oct 9.
PMID: 25291291BACKGROUNDFearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012 Aug 8;16(2):153-66. doi: 10.1016/j.cmet.2012.06.011. Epub 2012 Jul 12.
PMID: 22795476BACKGROUND
Biospecimen
peripheral blood sample
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kang Yu
Peking Union Medical College Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 14, 2020
First Posted
October 20, 2020
Study Start
November 1, 2020
Primary Completion
May 1, 2021
Study Completion
June 1, 2021
Last Updated
October 20, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share